Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

ELITE MEDICAL LABORATORY SOLUTIONS LLC

NPI: 1366820870 · TOMBALL, TX 77375 · Clinical Medical Laboratory · NPI assigned 05/16/2015

$1.03M
Total Medicaid Paid
58,404
Total Claims
32,274
Beneficiaries
103
Codes Billed
2018-05
First Month
2023-04
Last Month

Provider Details

Authorized OfficialALSAAB, SAAD (PRESIDENT)
Parent OrganizationPENTA STATE LLC
NPI Enumeration Date05/16/2015

Related Entities

Other providers sharing the same authorized official: ALSAAB, SAAD

ProviderCityStateTotal Paid
GRAHAM TOMBALL LLC TOMBALL TX $386K

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 81 $0.00
2020 13,259 $150K
2021 27,768 $523K
2022 11,933 $278K
2023 5,363 $82K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
81408 3,185 1,436 $222K
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 7,726 3,141 $213K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 4,373 2,617 $97K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 2,669 1,879 $95K
0051U 707 435 $47K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 4,465 2,556 $40K
81162 27 26 $32K
81407 1,382 1,150 $32K
81405 2,974 1,338 $25K
86003 617 552 $24K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 2,740 1,242 $24K
81406 2,972 1,338 $23K
81404 2,874 1,335 $22K
81403 2,580 1,197 $15K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets 182 136 $14K
81307 27 26 $12K
G2024 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source 1,849 561 $9K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism 3,238 472 $9K
81401 1,030 621 $7K
82785 600 543 $7K
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 298 275 $4K
81320 14 13 $4K
87631 132 122 $3K
81400 617 420 $3K
87486 484 368 $3K
81286 308 287 $2K
87581 473 357 $2K
81256 331 306 $2K
80061 Lipid panel 283 264 $2K
84443 Thyroid stimulating hormone (TSH) 169 157 $2K
81350 68 39 $2K
81344 16 15 $2K
81179 16 15 $2K
87481 773 192 $2K
80053 Comprehensive metabolic panel 284 265 $2K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc 138 89 $2K
83036 Hemoglobin; glycosylated (A1C) 247 231 $1K
81226 120 61 $1K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 253 217 $1K
87551 179 154 $1K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe 216 187 $1K
87496 216 187 $1K
87556 180 155 $1K
87500 218 189 $996.44
87640 244 207 $982.17
85025 Blood count; complete (CBC), automated, and automated differential WBC count 256 238 $981.44
87653 215 187 $935.62
87641 215 187 $907.55
87532 181 156 $850.94
87561 180 155 $850.94
87541 181 156 $850.94
87498 181 156 $820.53
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 264 143 $796.94
83540 105 97 $532.26
82670 74 60 $514.05
84403 75 61 $474.72
86225 124 114 $467.01
86038 125 115 $410.98
82627 75 61 $408.94
84270 74 60 $399.74
84144 72 58 $383.64
83001 74 60 $341.78
82533 33 27 $339.04
84481 32 27 $338.75
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 116 72 $337.81
82607 34 28 $313.56
86021 29 26 $313.04
82746 26 23 $270.48
86200 29 26 $269.36
86141 34 28 $269.36
86376 31 25 $267.72
86803 105 96 $252.45
82728 31 25 $250.70
86702 51 45 $231.16
84466 26 23 $224.40
83520 59 26 $220.96
86709 106 97 $208.13
84146 60 50 $201.50
87340 107 96 $191.02
84439 32 27 $180.25
86696 41 38 $179.77
86780 77 70 $173.31
86701 53 47 $170.12
84702 122 108 $168.45
86706 21 19 $163.21
83735 28 25 $134.00
86695 41 38 $122.09
86431 58 26 $113.25
82390 54 51 $99.33
84550 29 26 $93.86
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 14 12 $68.45
85652 26 23 $49.68
86703 31 29 $42.08
81355 34 32 $38.53
86705 82 74 $10.59
81479 Unlisted molecular pathology procedure 1,485 1,212 $0.00
81328 94 59 $0.00
81192 13 13 $0.00
83002 70 59 $0.00
81225 25 25 $0.00
81230 43 35 $0.00
81231 43 35 $0.00
81227 14 14 $0.00